[도1]


RT
Area
% Area
EP Plate Count
Resolution
Symmetry Factor
1 6.93 21413 2.78 1301
2 7.87 750101 97.22 3378 1.4 1.2
6.932
7.869
AU
0.030
0.020
0.010
0.000
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
Minutes

[도2]


RT
Area
% Area
EP Plate Count
Resolution
Symmetry Factor
1 6.95 26515 3.31 1352
2 7.91 773572 96.69 3540 1.5 1.2
6.952
7.912
AU
0.040
0.030
0.020
0.010
0.000
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
Minutes

WO 2025/084859 PCT/KR2024/015905

규칙 91,
13.12.2024

[도3]



[도4]

규칙 91,
13.12.2024



WO 2025/084859 PCT/KR2024/015905

규칙 91,
13.12.2024

[도5]



WO 2025/084859 PCT/KR2024/015905

규칙 91,
13.12.2024

[도6]



[도7]

규칙 91,
13.12.2024



[도8]


SUM190PT
SUM190PT, P1&P2
(N=4)
PBX-7016-P1
PADCEV-P1
Enf-PBX-7016 (DAR 7.9)
P63-PBX-7016 (DAR 8)
P63-PBX-7016 (DAR 4)
PBX7016-P2
PADCEV-P2
MMAE
Exatecan
Viability (%)
Concentration (nM)
PC-3 (Negative Control)
PC3-P1&P2
(N=4)
PBX-7016-P1
PADCEV-P1
Enf-PBX-7016 (DAR 7.9)
P63-PBX-7016 (DAR 8)
P63-PBX-7016 (DAR 4)
PBX-7016-P2
PAD-CEV-P2
MMAE
Exatecan
Viability (%)
Concentration (nM)

[도9]


H332M
H322M, P1&P2
(N=4)
PBX-7016-P1
PADCEV-P1
Enf-PBX-7016 (DAR 7.9)
P63-PBX-7016 (DAR 8)
P63-PBX-7016 (DAR 4)
PBX-7016-P2
PADCEV-P2
MMAE
Exatecan
Viability (%)
Concentration (nM)
PC-3 (Negative Control)
PC3-P1&P2
(N=2)
PBX-7016-P1
PADCEV-P1
Enf-PBX-7016 (DAR 7.9)
P63-PBX-7016 (DAR 8)
P63-PBX-7016 (DAR 4)
PBX-7016-P2
PAD-CEV-P2
MMAE
Exatecan
Viability (%)
Concentration (nM)

[도10]


N4-HEK293
Nectin-4-HEK293
(N=4)
Viability (%)
Concentration (nM)
PBX-7016
Enf-PBX-7016 (DAR 7.9)
Enf-PBX-7016 (DAR 4.1)
P63-PBX-7016 (DAR 8)
MMAE
PADCEV

[도11]


T47D
Viability (%)
Concentration (nM)
PBX-7016
Enf-PBX-7016 (DAR 7.9)
Enf-PBX-7016 (DAR 4.1)
P63-PBX-7016 (DAR 8)
P63-PBX-7016 (DAR 4)
PADCEV

[도12]


OD (450-640 nm)
Enfortumab mAb(ng/mL)
Mouse
Rat
Cynomolgus
Human

[도13]


A
Mouse Nectin-4
OD (450-640 nm)
Conc. (ng/mL)
Enfortumab mAb
Enfortumab-PBX-7016
B
Rat Nectin-4
C
Cynomolgus Nectin-4
D
Human Nectin-4

[도14]


A
Human Nectin-1
OD (450-640 nm)
Conc. (ng/mL)
Enfortumab mAb
Enfortumab-PBX-7016
B
Human Nectin-2
C
Human Nectin-3
D
Human Nectin-4

[도15]


Group 01, Isotype mAb, 5mg/kg
Group 02, Palbociclib, 50mg/kg
Group 03, Isotype-MMAE, 2.5mg/kg
Group 04, Isotype-MMAE, 5mg/kg
Group 05, Isotype-PBX-7016 (DAR4), 2.5mg/kg
Group 06, Isotype-PBX-7016 (DAR4), 5mg/kg
Group 07, Isotype-PBX-7016 (DAR8), 2.5mg/kg
Group 08, Isotype-PBX-7016 (DAR8),5mg/kg
Group 09, Padcev, 2.5mg/kg
Group 10, Padcev, 5mg/kg
Group 11, Enfortumab-PBX-7016 (DAR4), 2.5mg/kg
Group 12, Enfortumab-PBX-7016 (DAR4), 5mg/kg
Group 13, Enfortumab-PBX-7016 (DAR8), 2.5mg/kg
Group 14, Enfortumab-PBX-7016 (DAR8), 5mg/kg
Body weight change (%)
25
20
15
10
5
0
-5
-10
0
7
14
21
28
Days

[도16]


Group 01, Isotype mAb, 5mg/kg
Group 02, Palbociclib, 50mg/kg
Group 03, Isotype-MMAE, 2.5mg/kg
Group 04, Isotype-MMAE, 5mg/kg
Group 05, Isotype-PBX-7016 (DAR4), 2.5mg/kg
Group 06, Isotype-PBX-7016 (DAR4), 5mg/kg
Group 07, Isotype-PBX-7016 (DAR8), 2.5mg/kg
Group 08, Isotype-PBX-7016 (DAR8),5mg/kg
Group 09, Padcev, 2.5mg/kg
Group 10, Padcev, 5mg/kg
Group 11, Enfortumab-PBX-7016 (DAR4), 2.5mg/kg
Group 12, Enfortumab-PBX-7016 (DAR4), 5mg/kg
Group 13, Enfortumab-PBX-7016 (DAR8), 2.5mg/kg
Group 14, Enfortumab-PBX-7016 (DAR8), 5mg/kg
Tumor volume (mm3)
1400
1200
1000
800
600
400
200
0
0
7
14
21
28
Days

[도17]


Group 01, Isotype mAb, 10mg/kg
Group 02, Isotype-PBX-7016 (DAR8),10mg/kg
Group 03, Padcev, 5mg/kg
Group 04, Padcev, 10mg/kg
Group 05, Enfortumab-PBX-7016 (DAR4), 5mg/kg
Group 06, Enfortumab-PBX-7016 (DAR4),10mg/kg
Group 07, Enfortumab-PBX-7016 (DAR8), 5mg/kg
Group 08, Enfortumab-PBX-7016 (DAR8),10mg/kg
Body Weight Change (%)
30
20
10
0
-10
-20
-30
0
7
14
21
28
Days

[도18]


Group 01, Isotype Mab,10mg/kg
Group 02, Isotype-PBX-7016 (DAR8),10mg/kg
Group 03, Padcev, 5mg/kg
Group 04, Padcev,10mg/kg
Group 05, Enfortumab-PBX-7016 (DAR4), 5mg/kg
Group 06, Enfortumab-PBX-7016 (DAR4),10mg/kg
Group 07, Enfortumab-PBX-7016 (DAR8), 5mg/kg
Group 08, Enfortumab-PBX-7016 (DAR8),10mg/kg
Tumor volume (mm3)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
7
14
21
28
Days